Project Details
Description
Direct-Acting Oral Anticoagulants (DOACs) – apixaban, dabigatran, edoxaban, and rivaroxaban – have emerged and are being used as alternatives to vitamin k antagonists for the prevention and treatment of different cardiovascular conditions (1,2). Since the DOACs first approval in the UK in 2008 (3), they have become the preferred choice for anticoagulation, because of their documented non-inferior efficacy and safety in large randomized prospective trials and real-world observational studies, and because of their much more convenience to use (4-6). With the rapid uptake of DOACs, prescribers are faced with increasingly complex decisions relating to appropriate agent and appropriate dose to be prescribed (7). This review will explore and provide an overview of the factors influencing the prescribing of DOACs in general.
Short title | scoping review protocol |
---|---|
Status | Finished |
Effective start/end date | 2/01/23 → 29/12/23 |
Keywords
- (Anticoagulants; Anticoagulant agent, anticoagulant drug, oral anticoagulation, Direct thrombin inhibitor, Factor Xa inhibitors, Apixaban; Dabigatran; Edoxaban; Rivaroxaban; prescribing trends; prescribing pattern; factors affecting prescribing; Prescribing data, Drug prescription, Drug utilisation, Treatment decision making, Drug choice, Prescribing behaviour)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.